Mankind Q1 Results: PAT Jumps 29% as Revenue Grows 13% in Q1 FY27

What Happened ?

Mankind Pharma reported strong Q1 FY27 earnings driven by healthy growth across its domestic formulations business, continued expansion in chronic therapies, strong specialty performance following the BSV acquisition, and robust export growth. Margin expansion was supported by disciplined execution and improved operating efficiencies, while the company continued strengthening its leadership in the Indian pharmaceutical market.

key details

Key Highlights

• Revenue from operations increased 12.9% YoY to ₹4,031 crore.
• EBITDA rose 24.7% YoY to ₹1,060 crore.
• EBITDA margin expanded by 250 basis points to 26.3%.
• PAT increased 29.1% YoY to ₹574 crore.
• PAT margin improved to 14.2%.
• Domestic pharmaceutical revenue (excluding Consumer Healthcare) grew 11.0% YoY.
• Domestic prescription business delivered:
  • 15.8% growth in chronic therapies.
  • 19.4% growth in Cardiac.
  • 12.7% growth in Anti-Diabetes.
• Acute therapies showed recovery led by:
  • Gastro.
  • VMN.
  • Gynaecology.
• BSV specialty business recorded strong double-digit domestic growth.
• Consumer Healthcare revenue increased 3.9%, while gaining market share in key brands including:
  • Manforce.
  • Prega News.
  • Gas-O-Fast.
• Modern Trade and E-commerce contribution increased to 15% from 11% a year earlier, supported by 38% growth.
• Export revenue increased 29% YoY to ₹605 crore.
• Added one new product in the US market during Q1 FY27, taking total launches to 49 products.
• Maintained the No.1 prescription market position in India for the ninth consecutive year with a 15.2% prescription share.

Business Impact:

• Mankind continued strengthening its leadership in India’s pharmaceutical market through robust prescription growth, increasing chronic therapy contribution, and continued expansion of its specialty portfolio. Strong export momentum, improved operating margins, and growing presence across modern trade and e-commerce channels provide a solid foundation for sustainable long-term growth.

Risk Analysis

Summary:

• Although operating performance remains strong, future growth will depend on sustaining domestic prescription momentum, expanding exports, integrating specialty businesses, and navigating pricing and regulatory dynamics in domestic and international pharmaceutical markets.

Key Risks:

• Growth remains dependent on sustained prescription demand.
• Consumer Healthcare growth moderated during the quarter.
• Export performance depends on successful product launches and regulatory approvals.
• Pricing pressure and regulatory changes could affect profitability.
• Raw material and currency fluctuations may impact margins.

Worst Case:

• If domestic prescription growth slows, export momentum weakens, or regulatory and pricing pressures intensify, earnings growth and margin expansion could moderate in future quarters.

Risk Level: Medium

Company Commentary

According to Mankind Pharma:

• Management highlighted strong double-digit revenue growth supported by improved business fundamentals.
• Chronic therapies, particularly Cardiac and Anti-Diabetes, continued to outperform the broader market.
• The BSV specialty business delivered strong domestic growth, while exports increased significantly.
• Management stated that disciplined execution and strengthening operating fundamentals position the company to deliver sustainable long-term growth.